Cullinan Oncology is a late-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy designed to treat non-muscle invasive bladder cancer by directly eliminating cancer cells through selective viral replication while simultaneously activating the body's anti-tumor immune responses. The company is pursuing cretostimogene across multiple bladder cancer patient populations representing a substantial addressable market, with clinical data demonstrating favorable safety profiles and durable response rates. Cullinan intends to commercialize the therapy in the United States through its own sales organization while licensing international rights to partners in Asia and China, generating revenue from product sales and milestone or royalty payments from regional licensees.